Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 202.20M | 214.07M | 344.07M | 399.66M | 360.69M | 308.69M |
Gross Profit | 49.68M | 55.20M | 104.17M | 170.79M | 158.43M | 136.86M |
EBITDA | 29.30M | 29.82M | 74.75M | 130.03M | 117.02M | 106.19M |
Net Income | 18.98M | 9.67M | 48.80M | 87.83M | 81.78M | 63.58M |
Balance Sheet | ||||||
Total Assets | 532.65M | 540.31M | 528.53M | 501.53M | 395.94M | 209.26M |
Cash, Cash Equivalents and Short-Term Investments | 283.25M | 229.67M | 286.27M | 282.26M | 176.09M | 73.19M |
Total Debt | 138.00K | 135.00K | 72.00K | 393.00K | 410.00K | 5.54M |
Total Liabilities | 47.13M | 56.08M | 55.64M | 78.60M | 58.58M | 74.43M |
Stockholders Equity | 485.52M | 484.23M | 472.89M | 422.93M | 337.36M | 134.83M |
Cash Flow | ||||||
Free Cash Flow | -7.64M | -55.32M | 3.38M | 114.06M | -12.87M | 47.31M |
Operating Cash Flow | -7.69M | 58.98M | 8.48M | 125.79M | 57.60M | 47.92M |
Investing Cash Flow | -765.50K | -115.49M | -4.19M | -11.05M | -70.05M | -611.29K |
Financing Cash Flow | 0.00 | -144.00K | -326.00K | -8.73M | 115.76M | -5.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | HK$5.54B | 12.09 | 8.59% | 3.25% | 13.59% | 6.31% | |
74 Outperform | HK$6.32B | 7.08 | 10.85% | 5.95% | -20.64% | -25.39% | |
60 Neutral | HK$496.80M | 20.12 | 3.98% | ― | -15.96% | 32.95% | |
52 Neutral | HK$739.29M | ― | -47.91% | 1.87% | -18.98% | -164.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$536.71M | ― | -40.38% | ― | -43.46% | -96.48% | |
49 Neutral | HK$2.99B | 563.64 | 0.22% | ― | -4.38% | ― |
Modern Chinese Medicine Group Co., Ltd. reported a 15.4% decrease in revenue to RMB64.8 million for the first half of 2025 compared to the previous year. Despite the revenue decline, the company turned its financial performance around, achieving a profit of RMB2.5 million compared to a loss of RMB6.9 million in the same period last year, indicating improved cost management and operational efficiency.
The most recent analyst rating on (HK:1643) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Modern Chinese Medicine Group Co. Ltd. stock, see the HK:1643 Stock Forecast page.
Modern Chinese Medicine Group Co., Ltd. announced a positive profit alert, expecting a profit of at least RMB2.0 million for the first half of 2025, compared to a loss of RMB6.9 million in the same period of 2024. This turnaround is attributed to a significant decrease in disposal loss on property, plant, and equipment. However, the company anticipates a revenue decline of 15% to 20% due to intense industry competition.
Modern Chinese Medicine Group Co., Ltd. has announced that its board of directors will meet on August 29, 2025, to consider and approve the interim results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and future dividend policies, which are crucial for stakeholders and investors.